Appendix 4D and Half Yearly Accounts
Filed with ASX · · 19 pages · English
Dividends There were no dividends paid, recommended or declared during the current financial period. Comments The loss for the company after providing for income tax amounted to $1,983,363 (31 December 2024: $1,950,364). The current year loss was after receiving Research and Development Tax Incentives of $1,717,150. The company has continued clinical trials in the US and in Australia, and is progr
Earlier from CLEO Diagnostics
- CLEO Confirms Next-Gen Platform for Ovarian Cancer Test
- Quarterly activities and cashflow report
- CLEO Raises $5m to Support U.S. Market Launch
- Trading Halt
- Cleo Strengthens Cash Position with $1.7m R&D Tax Refund
Later from CLEO Diagnostics
- CLEO Optimises Biomarker Panel Ahead of FDA Submission
- Sample Collection Completion for Pivotal US Clinical Trial
- CLEO Commences Kit Manufacturing Ahead of FDA Submission
- CLEO Establishes U.S. Reimbursement Pathway
- CLEO Enters Analytical Validation Phase
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics